Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

November 3, 2020

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 67 min

Earnings Call Speaker Segments

Operator

operator
#1

Thanks for joining Bayer AG's press conference. <<operator_script>> Please note that this conference is being recorded. <<operator_script>> At this point, I'll turn things over to Dr. Michael Preuss, Head of Bayer Group Communications.

Michael Preuss

executive
#2

Many thanks, Ms. Ent. Good day, everyone, and a very warm welcome to our conference call about the release of the third-quarter 2020 results. We truly appreciate your interest and your participation. We hope you are well and in good health during these difficult times. Joining me at the table are Bayer AG's CEO, Mr. Werner Baumann, and Mr. Wolfgang Nickl, CFO of Bayer AG. They will begin by giving you the key figures on business development, and afterward we will move on to the Q&A session. Before we start, I would like to point out the forward-looking information and also remind you to keep in mind all of the information we have provided. I would now like to hand the floor to Werner Baumann.

Werner Baumann

executive
#3

Thank you. Ladies and gentlemen, I'd like to welcome you as well to today's conference call. Along with Wolfgang Nickl, I'd now like to walk you through the key developments from the third quarter of 2020, and we look forward to taking your questions afterward. First, let me say that although our Crop Science business saw a seasonally weak third quarter, we're confident we can meet, on an operational level, the revised full year outlook we issued in August. Across the first 9 months of the year, we kept business performance steady versus the prior year period on a currency- and portfolio-adjusted basis. That also holds for core earnings per share, which reached EUR 5.07 and therefore match the prior year level despite negative currency effects. This clearly shows that we're active in the right markets and that Bayer is well positioned to overcome this unprecedented coronavirus crisis, bolstered by a resilient business and motivated workforce. Like all companies, we have faced major challenges in 2020 that we hadn't been expecting at the beginning of the year. Even during the first wave of the pandemic, we did everything in our power to ensure that our employees and their families received the very best protection and support.

Werner Baumann

executive
#4

We've given customers, patients, and farmers a dependable supply of products that, in certain cases, save lives. We've also opened our labs and the whole company, and numerous volunteers from our own workforce have offered tremendous assistance with testing equipment and medicines, along with donations of money and equipment. We've learned how to respond to the pandemic and have worked to make sure we're as well equipped as possible to tackle it. In recent weeks, the number of infections has again been climbing quickly. Governments worldwide are putting in place comprehensive protective measures and substantial restrictions on public life and in private settings. All of us realize the virus will stay with us for a long period of time. And here at Bayer, we'll keep doing everything we can to make sure our employees are safe, that patients, consumers, and farmers receive their products, and that we honor our social responsibility as a good corporate citizen. That's what we stand for, as does our vision, "Health for all, hunger for none." Before I hand things over to Wolfgang Nickl to walk you through the key details of our third quarter performance, I'd like to review some additional developments from recent months.

Werner Baumann

executive
#5

Let me begin with a quick status report on the glyphosate litigation. Following the broad agreement reached with counsel for the plaintiffs, we began this summer putting those individual settlement deals into effect for the active Roundup matters. To date, we have secured a deal that covers roughly 88,500 claims. Discussions aimed at settling with a substantial share of the remaining claimants are proceeding with Ken Feinberg serving as mediator. That covers where the current cases stand. Turning to potential future Roundup claims, we are working with the plaintiffs' counsel on a detailed settlement agreement — built on the memorandum of understanding finalized at the start of September — that responds to the court's concerns. It is already clear that this revised proposal will carry a cost of approximately $2 billion beyond the USD 1.25 billion originally anticipated. We anticipate wrapping up the formal agreement within the coming weeks, after which we will submit a motion for preliminary approval to the court. As I mentioned earlier, we expect our business to remain stable in 2020 in spite of all the headwinds. We actually foresee currency-adjusted EBITDA before special items rising versus 2019. And for 2021, we likewise expect sales to match the 2020 level, even though earnings are projected to fall year-on-year. That said, given present conditions, the Bayer Group will be unable to hit its original target of 4% to 5% annual growth.

Werner Baumann

executive
#6

Part of this comes from unfavorable currency movements and a steep drop in pricing within China. Given that situation, on September 30 we made an ad hoc disclosure announcing that, according to our planning, we would not be able to satisfy the more optimistic market expectations for 2021. We further announced noncash impairment charges tied to our agricultural business, which we detailed today. Simultaneously, we announced a set of countermeasures, including speeding up existing efficiency programs and finding additional cost savings. We are additionally examining options to exit nonstrategic businesses beneath the divisional level. The savings we achieve will mainly be used for further investment in innovation and profitable growth opportunities, and for pushing forward our debt reduction efforts, bolt-on acquisitions and in-licensing our plans in Pharmaceuticals and Consumer Health, in particular. Given that situation, I am pleased to report that we have successfully concluded negotiations to acquire AskBio, as announced last week. AskBio is an American pharmaceutical company specializing in the research, development and manufacture of gene therapies across various therapeutic areas. This acquisition substantially strengthens our position in cell and gene therapies. AskBio's development portfolio includes attractive preclinical and clinical-stage candidates for treating neuromuscular, central nervous system, cardiovascular and metabolic diseases as well as disease of the central nervous system.

Werner Baumann

executive
#7

That covers therapeutics aimed at Parkinson's disease and congestive heart failure, along with clinical candidates for hemophilia, just to give a few examples. AskBio should produce a substantial quantity of new products annually across the short, medium and long term. Taking into account the investments currently underway plus our Pharmaceuticals and leaps partnerships, the majority stake acquisition through the purchase of KaNDy Therapeutics and now AskBio, we've put almost EUR 3 billion into our Pharmaceuticals and Consumer Health businesses this year, and that comes on top of ongoing R&D investment of roughly another EUR 3 billion in this field. As you can see, even in a challenging year like 2020, we're consistently seizing opportunities that come up and investing in for future growth. We also got some good news for our agricultural business last week when the U.S. EPA, Environmental Protection Agency, announced a new 5-year registration for dicamba, our herbicide. That's really great news for U.S. farmers and also for the competitive profile of our soy and cotton business in the years ahead. That brings me to the end of my general remarks, so we can now move on to the data for the third quarter, which Wolfgang Nickl will present.

Wolfgang Nickl

executive
#8

Thanks a lot, Werner, and a very warm welcome from my side as well. The third quarter of 2020 can be summarized like this. Our agricultural business faced a challenging quarter, while Pharmaceuticals recovered and Consumer Health delivered strong growth. Group sales came to EUR 8.5 billion in the third quarter, a decline of 5.1% versus the prior year. Please keep in mind that whenever I refer to sales, the figures are always adjusted for currency and portfolio effects. Group EBITDA before special items dropped 21.4% year-on-year, landing at EUR 1.8 billion. Earnings here were reduced by negative currency effects amounting to EUR 205 million. Core earnings per share from continuing operations fell to 81% (sic) EUR 0.81, mainly because earnings at Crop Science declined steeply. In the prior-year quarter, core earnings per share had reached EUR 1.16. Free cash flow — that is, total cash flow from business operations minus capital expenditures — amounted to EUR 1.2 billion in this year's third quarter. Let us now examine how our divisions performed, beginning with our agricultural business.

Wolfgang Nickl

executive
#9

Crop Science sales dropped 11.6% in the third quarter, on a currency- and portfolio-adjusted basis, to EUR 3.0 billion. North America saw a substantial sales decline, in particular, and that's where we had higher product returns and lower license revenues at Corn Seed & Traits, driven by planted acreages coming in below what we had anticipated. Herbicides also posted substantial declines against a strong prior-year quarter. The sales decrease was mainly in North America, though sales also fell in Europe, Middle East, Africa. In contrast, the Herbicides business grew in the Asia Pacific region. Fungicides sales rose across every region, helped by higher volumes. In Latin America, the main benefit came from the market's shift to our Fox Xpro product in Brazil. EBITDA before special items at Crop Science went from EUR 500 million in the prior-year period to minus EUR 34 million in the third quarter of 2020. That drop is largely due to the sales decline in North America plus a negative currency effect of EUR 123 million. Earnings also took a hit from technical effects and from shifts between reporting periods. Now let's turn to our Pharmaceuticals division. Pharmaceuticals sales fell 1.8% in the third quarter, to EUR 4.2 billion.

Wolfgang Nickl

executive
#10

Just like in the second quarter, the rollout of new tender procedures in China weighed on us. Strong volume growth allowed us to partially counterbalance that effect. The indications of recovery from COVID-19's worldwide impact, which had already started to show near the close of the prior quarter, mostly carried on, and that holds particularly for ophthalmology and women's health. For our oral anticoagulant Xarelto, we posted robust sales growth of 14%, mainly reflecting higher volumes in China, Germany and Russia. Sales of Eylea, our ophthalmology drug, keep climbing modestly versus a year earlier, once again fueled by the Eylea prefilled syringe launch and robust demand in China. EBITDA before special items at Pharmaceuticals rose 0.9% during the third quarter, reaching EUR 1.5 billion. Owing to rigorous cost management in this area, we managed to expand earnings and margin at Pharmaceuticals even with the modest sales decrease and unfavorable currency effects. Ladies and gentlemen, as you are aware, we keep working to reinforce the research pipeline at Pharmaceuticals. To back these efforts, we are pushing forward the next generation of innovation platforms featuring new mechanisms and putting money into in-licensing and bolt-on acquisitions.

Wolfgang Nickl

executive
#11

Werner Baumann has already covered our acquisitions, particularly the purchase of AskBio. Beyond a robust technology platform and clinical pipeline, AskBio is already bringing in revenues of its own, so it will contribute to Bayer's growth right from the start. We're also achieving significant headway in our own research work. Only a few days ago, we presented positive data for finerenone from a Phase III trial involving patients with chronic kidney disease and type 2 diabetes. And shortly before that, we announced positive data from a clinical Phase III trial in oncology investigating copanlisib in combination with rituximab. All of this is encouraging news for the future of our Pharmaceuticals business. That brings us now to our Consumer Health division. Sales of our self-care products climbed by 6.2% in the third quarter to EUR 1.2 billion. Following the anticipated reduction of trait inventories in the second quarter, the growth trend carried on at Consumer Health, with a substantial rise in sales. In this area, the Nutritionals category especially gained from consumers putting a greater emphasis on prevention and their own health in general during the pandemic. Business in the Nutritionals category was up across all regions, with growth of 21.4%. In North America, we recorded double-digit percentage growth, driven by continued strong demand, particularly for our One A Day vitamins.

Wolfgang Nickl

executive
#12

We also got a boost here from extending our product lines. The digestive health category saw sales rise 14%. Conversely, sales in the allergy and cold category fell, which was largely the result of stronger protective and hygiene practices adopted in reaction to COVID-19. EBITDA before special items rose 12.3% in the third quarter, driven mainly by the large sales gain and by favorable effects from the efficiency program we started late in 2018. That concludes what I wanted to say about our third quarter performance, so I'll turn now to the outlook for the full year 2020. I believe we all recognize that fiscal year 2020 has been extremely difficult in every respect. That applies to every country and industry and, naturally, it affects our company too. Early in the year, we issued our 2020 forecast without factoring in any potential impact from COVID-19. Given how our business performed during the first 6 months — including a very strong first quarter — while also allowing for the numerous uncertainties and the headwinds we could foresee, we revised our 2020 outlook during the summer.

Wolfgang Nickl

executive
#13

At that point, we stated that we anticipated overall normalization of business at Pharmaceuticals and Consumer Health. As for our agricultural segment, we had already indicated during the summer that we foresaw a softer second half, with significant currency headwinds. As Werner noted at the outset, on the whole, our operations during the first 9 months of the year were flat versus the same period a year earlier. That is likewise what becomes apparent when you examine the sales and earnings figures shown on this slide. Against that background, we are able today to affirm that our revised group outlook for the full year 2020, on a currency-adjusted basis, holds firm despite the difficult times and the economic crisis we are currently facing. The next slide shows what that outlook looks like and what we anticipate in detail. We continue to anticipate sales landing between EUR 43 billion and EUR 44 billion on a currency-adjusted basis. Our goal is to raise the EBITDA margin before special items to roughly 28% on a currency-adjusted basis. On the sales side, that would translate into EBITDA before special items of approximately EUR 12.1 billion. With respect to core earnings per share, we anticipate a currency-adjusted rise to between EUR 6.70 and EUR 6.90.

Wolfgang Nickl

executive
#14

We expect currency headwinds once more in the fourth quarter. Roughly 80% of our net sales are generated by our company in currencies other than the euro. So our business is especially exposed to the considerable currency fluctuations that we have seen stemming from the pandemic. And now I will hand things back to Werner.

Werner Baumann

executive
#15

Thank you, Wolfgang. Ladies and gentlemen, at this moment we find ourselves in a global crisis without parallel—one that places enormous strain on everyone and is bringing about profound shifts at the personal, social, cultural, and economic levels. Even so, it is clear in this situation too that each crisis carries within it an opportunity, and that holds true for Bayer as well. The significance of the fields we operate in—health care and nutrition—has never been more evident than it is today. Through the pandemic we have seen just how vital our health is, not only for each of us as individuals but also for society as a whole, for our modern economy, and for our prosperity. In the past, discussions were often dominated by the rising costs of health care. Now, however, we have an opportunity to regard health care as an investment in quality of life and prosperity. At the same time, the pandemic is once again turning a spotlight on global nutrition. The reason is that this crisis hits the poorest among us hardest and therefore threatens to worsen world hunger. According to the global nutrition report, the COVID-19 pandemic could drive as many as 130 million additional people into chronic hunger by the end of 2020. And the fact that this year's Nobel Peace Prize was awarded to the World Food Programme of the United Nations also underscores how large and indeed how urgent the challenges are in this area.

Werner Baumann

executive
#16

With that as the background, we stay absolutely certain that ours is the correct line of business, since nowhere else does the enormous demand for fresh solutions line up so encouragingly with scientific progress as it does in these areas. The 2020 Nobel Peace — actually the Nobel Prize for chemistry this time — also highlights this point. That award, as you're aware, went to Emmanuelle Charpentier and Jennifer Doudna, the inventors of the genome editing technique CRISPR/Cas9. In honoring them, The Royal Swedish Academy of Sciences recognized a research field that unlocks vast possibilities in medicine as well as plant breeding, and so stands as an illustration of the immense innovative promise held by the life sciences. In fact, 8 of the most recent 10 Nobel Prizes in Chemistry went to researchers whose discoveries concerned the realm of genes and proteins. Experts call this realm the Bio Revolution, and within it the lines separating biology from artificial intelligence grow ever more indistinct. When it comes to capturing the Bio Revolution's long-term innovative promise across health and agriculture, Bayer is positioned better than nearly any other firm, and can therefore contribute crucially to answering some of humanity's most urgent questions: how do we feed as many as 10 billion people by 2050 in a world affected by climate change, and how do we secure quality of life for a rising number of elderly people?

Werner Baumann

executive
#17

Getting those questions answered is the foundation for our exceptional prospects for growth over the long term. That brings my presentation to a close. I appreciate your time. At this point, we're happy to take whatever questions you may have.

Michael Preuss

executive
#18

Thanks a lot, Werner Baumann, and thanks a lot, Wolfgang Nickl. Ladies and gentlemen, Ms. Ent will explain how you can go ahead and ask your questions now.

Operator

operator
#19

<<interpreted>> <<operator_script>> Our first question comes from Hendrik Jan Beck of Der Tagesspiegel.

Speaker

unknown
#20

I've got a question about the Roundup litigation. Mr. Baumann, you mentioned that a settlement had been reached covering roughly 88,000 plaintiffs. There are several other lawsuits still in progress. So how many cases remain open and active? And my second question is: what approach are you taking to resolve future settlements and to try to establish legal certainty here? That was a real point of contention.

Werner Baumann

executive
#21

Thanks a lot, Jan Beck, for that question. On your first one: with regard to those 88,500 suits, we've in fact now reached a settlement — and beyond that, there are additional plaintiffs we're in talks with at present. As of 24 June, we had the 120,000 cases we referred to. We don't have a newer number for you right now, since naturally the count of suits and cases has to be checked to see whether each one is actually valid. So that's the reference point I can give you today. On your second question: at the start of September we already announced that we were in discussions with representatives of future affected persons about this memorandum of understanding, as it is called. That memorandum of understanding deals with the concerns Judge Chhabria set out on 6 July, and at the moment we are working to enshrine it as a contract. In the weeks ahead, we will be submitting it to Judge Chhabria for preliminary approval.

Operator

operator
#22

The following question comes from Jonas Jansen, who writes for FAZ newspaper.

Jonas Jansen

unknown
#23

In your ad hoc announcement, you mentioned negative effects. My suspicion is that those effects have now grown more severe. I also suspect that glyphosate's negative impact will be more severe as well. So what I'd like to know is how you view the future. And also, the Monsanto acquisition, looking at it from today's perspective — was that a good idea?

Werner Baumann

executive
#24

Thanks a lot for that question. We did lay out a framework for where we'd land with our adjustments, and that was tied to the September 30 deadline. We remain inside the range we communicated. And as you pointed out, we're actually still in the upper part of that framework. Glyphosate costs a bit more. We already said specifically here that this falls under implementation of the memorandum of understanding, referring to the adjustments we've introduced to account for Judge Chhabria's consent. And we're talking about $750 million, and this concerns the future only. I hope that answers your question.

Operator

operator
#25

And now we'll take the following question, which comes from Reuters.

Speaker

unknown
#26

Could you tell us what's different going forward? My second question concerns the amortization and write-offs — I'd appreciate more detail on those, please. And can you give us a timeframe for when the existing cases will be dealt with?

Werner Baumann

executive
#27

I'll start with the first question and then move to the last one. As for how the split between Monsanto and Bayer works, Mr. Nickl will address that. Details about the memorandum of understanding negotiations and its implementation are, of course, confidential. That means aside from what has already been communicated, I'm unable to share anything further. I'd ask you to please understand this. All I can say is that the framework for these negotiations — and the other negotiations we're involved in — does address the judge's concerns to his satisfaction, at least in our view. It will also account for anyone who may become ill down the road. Regarding the timeline for resolving the existing cases, I can only say that active negotiations are underway right now, and this is a process we don't fully control ourselves, of course. That means we must wait and see what comes out of the negotiations within the framework we've established. But we're confident. And you can see that if you look at the numbers we've received so far.

Werner Baumann

executive
#28

So we feel good that over the coming few months, we're going to witness even more meaningful improvement.

Wolfgang Nickl

executive
#29

Yes, let me address the depreciation write-offs question. So the figure is roughly EUR 9.3 billion. It's difficult to pinpoint precisely how much relates to Monsanto versus Bayer. We operate a single Crop Science business. Still, allow me to share 2 specifics. We're referring to EUR 7 billion in intangible assets across cash-generating units. That covers corn, soybeans, vegetables, and Roundup, plus approximately EUR 2 billion tied to goodwill. Let me also note something regarding the depreciation and the reason we landed at the upper end for the quarter — Werner touched on this too — it ties back to how things stood at quarter-end. I'd add that this depreciation stems from 2 separate factors. First, growth. Expectations for growth have come down, since last year brought no growth and this year has delivered very little. Beyond that, it's explicitly driven by currency and interest effects. On the overall depreciation amount, I can offer an order of magnitude. Roughly 2/3 stems from discount factors and weighted cost of capital, while 1/3 comes from growth. That should give you some context for why we originally had a range and why we now sit at the top end of it.

Operator

operator
#30

Moving on, our next question comes from Annette Becker with Börsen-Zeitung.

Annette Becker

unknown
#31

I've got 2 questions. The first one concerns your outlook. You mentioned the currency-adjusted figure and then the one excluding that. I mean the adjusted figure, the one that serves as the basis for your dividend policy of 30% to 40%. So which does that refer to — the figure with currency adjustments or the one without them? Then I'd also like to ask about the savings program you announced at the end of September. When do you expect to be in a position to share more details, especially concerning the costs? And will they be reflected in your numbers, in your balance sheet, during the current fiscal year?

Wolfgang Nickl

executive
#32

Ms. Becker, my name is Wolfgang Nickl. On your first question, our dividend policy is 30% to 40% of core EPS, including currencies. So that refers to the EUR 6.30 to EUR 6.50. And we said that quite probably we'll be at the lower end during this time period. Then the savings program, EUR 1.5 billion plus, we haven't specified that yet. This is, of course, being detailed right now in the different divisions and in different areas, of course, including the negotiations with labor representatives around the world. And very clearly, what's important is to continue to assure that Bayer is secured for the future, Bayer 2025, and this rules out redundancies or -- redundancies up until then. And seeing details right now, and the details will be available, I think, at the beginning of next year. And then we have our Capital Market Day, which will be at the end of February, probably early March. And by then we'll -- we hopefully will be able to tell you more details. Then measures with regard to savings in terms of overheads and manpower cost, well, it's hard to talk about one-off costs here. But just as a general indication, I can tell you that we have a factor of 1.7 that we mentioned in 2018 for this program.

Wolfgang Nickl

executive
#33

And if those measures aren’t something you know about, well, there’s no way to set aside any provisions at this point. So by the time this year wraps up, I don’t believe we should expect any provisions by then.

Operator

operator
#34

Moving on to the next question, we have Patrick Klevitz from Reuters.

Speaker

unknown
#35

Yes. I'd like to ask about the revised concept regarding the litigation and the reason behind it. I understand you won't be able to give us any details, but perhaps you can provide some general information. Maybe you could tell us what the revised strategy will apply to. Perhaps you'll have more clarification for next year as well. And maybe you can also tell us what the overall loss might be.

Werner Baumann

executive
#36

If I could just take your first question before handing things over to Wolfgang Nickl for a few words on the overall picture. Yes, I believe those figures are available in our guidance. And it's evident that everything — apart from the concept, which is presently under negotiation, and the fact that both sides have signed this memorandum of understanding — I can only restate what I've already said. No further details can be shared from my side here. These negotiations are confidential. We're operating under a closed memorandum of understanding, and the specifics are right now being negotiated and committed to writing. On that, I can't say anything additional. As for the second point on the nonstrategic operations, we've stated before that we will review our portfolio along with our nonstrategic operations. We view this as sitting outside the portfolio. It's an ongoing process at all times. We intend to step that up to some degree. In this quarter, for instance, we are divesting smaller brands that don't align with the overall portfolio. In Consumer Health, for instance, we're now examining somewhat larger divisions and business units that aren't necessarily a core part of our strategy. What exactly those will be, I'm unable to tell you at this moment.

Werner Baumann

executive
#37

Right now, at the management level, we're talking these through and analyzing them. And once we're able to inform you, well, an announcement from the Supervisory Board will follow after the agreement. As for any redundancies or job cuts, you should expect that redundancies will occur. But where those will happen and at what time, beyond the programs already known, I can't say. I can't give you any further details at this point, as Wolfgang Nickl has already stated. But -- and as Wolfgang said, this probably isn't expected until the end of the year.

Wolfgang Nickl

executive
#38

On the 2020 guidance, I’d like to make a few remarks. I also want to restate that core EPS, after currency effects—which have been significant—will come in at roughly EUR 6.30 to EUR 6.50. For comparison, last year the figure we discussed was EUR 6.38. So I don’t believe there’s any reason for us to hide behind the situation. Then, naturally, we have several special items. We’ve already discussed the impairment of EUR 9.3 billion. Earlier in the year, we also mentioned additional effects stemming from restructuring measures, amounting to somewhat more than EUR 1 billion. That, too, is known. And when we consider all the different lawsuits—dicamba, glyphosate, Essure, and so forth—the figure is around EUR 13 billion. All of that is partly offset by gains from the sale of the Animal Health business. That comes to an estimated EUR 5.2 billion. It should be noted, however, that this will of course be corrected, I believe around 120 days after conclusion. That will fall at some point in November. But those are the basic parameters for you to be aware of here.

Operator

operator
#39

Moving on to the next question, BPA.

Speaker

unknown
#40

So where do things stand now after the announcements you made regarding your divisions back in 2018, when 12,000 jobs were going to be eliminated? How many positions have actually been cut so far? And when will that process be finished?

Wolfgang Nickl

executive
#41

Thanks a lot for that question — this is Wolfgang Nickl speaking. We're seeing solid progress across several divisions. On the whole, the savings and sales synergies we announced back then totaled EUR 2.6 billion. This year we've delivered more than 30%. Originally, the plan was 40% this year and 60% next year, with everything wrapped up entirely by 2022. We're outperforming what we'd initially targeted. This year we'll be heading closer to 60%. Things have moved faster on our side. One-off costs remain well in line with plan — the factor there is 1.7. And, as you also pointed out, up to 12,000 positions. The precise number I can't give you. My recollection is that last year roughly 104,000 people were working for us. Right now we're at about 101,000, which means 3,000 to 3,500 people have been made redundant.

Speaker

unknown
#42

So out of that 12,000, what number has already been reduced? Since back in 2018, you had already started this process, right?

Wolfgang Nickl

executive
#43

Well, I’d need to verify those numbers. I don’t have them in front of me. All I know is that for this year, we’re referring to 3,500 people.

Speaker

unknown
#44

And that 60% you mentioned — the savings and synergies you're referring to — is that what you mean, the 60% you'll have achieved by year's end?

Wolfgang Nickl

executive
#45

Yes, that one's right.

Operator

operator
#46

Antje Höning from Rheinische Post has the next question.

Antje Höning

unknown
#47

I have 3 questions. I'd also like to hear about the job reductions. When you run the numbers, that comes to 7,000 positions being eliminated. 2.6 billion — that works out to 12,000. And with this latest figure, it's 7,000. Are those the correct numbers I'm seeing? Then I'd like to hear a bit about the dividend. Shareholders need to brace for a reduction. How large will that reduction be? And you never answered what the other colleague asked regarding the Monsanto purchase mistake. That was the FAZ colleague's question.

Werner Baumann

executive
#48

When it comes to how large the workforce reduction will be, there's nothing I can share with you at this moment. Wolfgang Nickl has already mentioned that the planning process is underway right now. We're likewise working on pinpointing the measures and fleshing out the details of those measures. Overheads will see cuts. And naturally, we'll reduce them as far as we're able to. Of course, that will include manpower costs as well. But how much of the total that will represent, I can't say at this moment. Even if I wished to, I couldn't state it. And that will be communicated next year. Then on the dividend, Wolfgang Nickl has truly already covered everything. We are, within the quarter, at 30% to 40% of core earnings per share. As for the dividend that management will propose, well, that has to be discussed by the Board of Management and Supervisory Board. And so, at this current point in time, there's nothing I can share with you on that. Beyond that, well, we discussed our agricultural business. And in my preliminary remarks, I said a fair amount about that, I think, regarding why we're fairly confident about that business.

Werner Baumann

executive
#49

Our confidence in this has never wavered, and that remains true. To be specific, the present crisis will not alter it. Let me restate what Wolfgang Nickl said: 2/3 of the value adjustment, or impairments, that we are observing comes from currency and interest specs, while 1/3 stems from changes in growth. Here, we need to recognize that when you set this against the market growth we initially considered — and we cannot separate ourselves from it — in 2019 and 2020 and '21, where I looked, the environment will be clearly weaker. Given how much weight the earlier years carry, this will significantly affect the valuation. Even so, we believe this business is very, very well positioned over the long term, thanks to the leading positions we hold here. Beyond that, the market will see long-term growth. That also has not changed. And I think we must separate two things here. The current situation is one matter — that is where things stand at this point in time, and you have to examine it. The strategic prospects for our business are the other.

Antje Höning

unknown
#50

And one more question. Given how dramatically the stock has fallen, to EUR 40, do you think Bayer could become a takeover candidate?

Werner Baumann

executive
#51

So business is solid. There’s a lot of value in this company. We don’t set the stock price. Our job is to run the company as well as we can. And then we believe that the value we see in the company will eventually show up in the share price at some point.

Operator

operator
#52

Moving on to the next question, please — the floor is yours.

Speaker

unknown
#53

On your ag business and that correction—you had cash tied up in several products, and it all ties back to the correction. Is there a direct link to the litigations in the U.S.A.? Because ultimately Monsanto's image has taken a fair amount of damage, and that could hurt demand for the product too. So in plain terms, do the litigations connect in any way to the changes here? And Monsanto, you've stated you're 100% convinced the purchase and acquisition was a good idea. Can you at least concede, with hindsight, that the price you paid was too high?

Werner Baumann

executive
#54

Thanks for asking that. Let me take you back briefly to 2016. What we paid back then came out of competitive bidding at the time, and we also had to consider Monsanto's stock levels. The price we paid was actually not that far from Monsanto's own market capitalization roughly 1.5 years earlier. So there isn't much more I can add on that. You always have to consider that particular moment in its context and then examine the activities that followed from it. On your second question, I'd like to hand things over to Wolfgang Nickl.

Wolfgang Nickl

executive
#55

So I’d answer that with a no. Naturally, at this point it’s quite hard to determine what the volume effects will be over the long term. It’s possible that one customer held off on buying because of the litigations. Still, I can tell you that even within the consumer segment, with Roundup in the U.S.A., we aren’t seeing any meaningful significant impact in those numbers — which is why, broadly speaking, I’d say no.

Operator

operator
#56

Moving on to the next question, from Ruth Bender at the Wall Street Journal.

Ruth Bender

unknown
#57

Yeah, I just wanted to bring up the glyphosate litigation, and also the California court turned down your appeal. How are you going to move forward on this? What does that mean for your long-term strategy to achieve success and also try to get a favorable ruling for yourselves?

Werner Baumann

executive
#58

Yes, Ms. Bender. I believe you're asking about the Johnson proceedings. Naturally, we're disappointed when it comes to the appeal. Right now we're reviewing what comes next on that appeal at the U.S. Supreme Court, and we're getting everything ready along those lines. And of course, for a lot of reasons, the case that matters most to us is the Hardeman case, since those proceedings move a bit faster — the possible proceedings at the U.S. Supreme Court.

Operator

operator
#59

Our following question comes from Jan Danisman at Bild.

Speaker

unknown
#60

I've got a question that relates to the guidance. Today's a really significant day — the U.S. elections are happening and there are new politicians. So we're able to see what sorts of donations have been made. We also have the political action campaign. And we see that they've been involved with the Republican candidate as well. But when it comes to Bayer's employees, more money has gone to Biden. And Mr. Baumann, back in 2016, Trump had just been elected. Well, would you be glad to see Trump win again, since you already have a connection? Or do you lean more toward your U.S. employees, who back Biden more strongly? Where do you stand on this as Bayer?

Werner Baumann

executive
#61

Thanks a lot for your questions. On the Political Action Committee — that's a committee whose members are solely employees, and they reach their own choices. It has no connection to the company at all, even though the committee carries the name BAYERPAC. And to be clear on this point, presidential candidates receiving support is not what we're discussing here. As for how the elections turn out, we're eagerly waiting to see what happens over the coming weeks, including the impact on our business. And our hope is that we'll be able to collaborate well with whichever administration is in place.

Operator

operator
#62

The next question comes from Renè Bush at APM Health Europe.

Speaker

unknown
#63

You said the deal has been agreed. Could you share some details on the AskBio acquisition? We'd like to hear more about how it affects the pipeline, and also about AskBio's late-stage pipeline in Pharmaceuticals.

Werner Baumann

executive
#64

Thanks for those questions, Ms. Bush. To start with, well, we do have certain products that were in the late-stage pipeline during the last 18 to 24 months, and those have now come out of it. And it's always a good thing to have products in this late pipeline rather than licensing, for example, in oncology, Vitrakvi and VKA. And in spite of the very tough licensing situation for our new product during the pandemic, we remain very hopeful here. We think this is very promising. And we believe that the revenues and growth rates will exceed our expectations. And in this situation, in particular, well, our plans call for normal business activities. And despite the pandemic, we see much more momentum here. And this is one of the biggest products in terms of its potential that we've got. Wolfgang Nickl already talked about the positive study results and the pipeline for copanlisib and finerenone. And that is another one of the biggest pipeline products in terms of potential revenues. He pointed these out. And of course, we did -- we've done a few other things too, which help us out in our medium- to long-term prospects.

Werner Baumann

executive
#65

Of course, beyond those near-term projects, there are reasons we feel good about our Pharmaceuticals business. To start with KaNDy Pharmaceuticals: that acquisition brings us late-stage pipeline assets in women's health. Women's health is an area where we lead globally, and this gives us a novel, effective mechanism for treating menopause. It's a highly attractive product, and next year it moves into Phase III of clinical testing, of clinical development. On top of that, we have high hopes for further advances with Neuro. There we're working in cell therapy, and it's going well. The preclinical studies, which have had better success, point to this. And we think this could open the door to the first potential curative treatment. That means a curative treatment for Parkinson's disease. Now, all of these are high-risk projects, of course, but you can see the potential and also how committed our organization is. You can see we take "Health for all and hunger for none" very seriously. And then last but not least, regarding AskBio, that's a really interesting company, because there's a great deal inside that company. So I'd like to thank you expressly for that question.

Werner Baumann

executive
#66

To start with, there's a huge patent portfolio at that company — a large patent repository that comes to us through this acquisition. Plus, they have a group working on AAV vectors that has been doing pioneering work for over 20 years. That know-how is now joining our company. And it can be applied across different divisions. It's similar to biotech 25 years ago, with the cell and gene therapy treatments being developed at many companies right now — there are chronic bottlenecks we can already foresee in production. AskBio is bringing us a production platform that is in the clinic right now, it's being set up at present, and it will likely be available in 2022. It will give us additional production capacity that brings growth and earnings and very attractive margins, on top of further building our experience in manufacturing these therapies. In addition, we already have a clinical portfolio of clinical candidates, development candidates in Phase I for <<inaudible>> disease and heart disease and also for Parkinson again. And over the coming years, as I mentioned, you have the R&D machine at AskBio.

Werner Baumann

executive
#67

And annually, without fail, additional development candidates keep emerging from that pipeline, and they’ll add substantially to what we have in the pipeline for the long term.

Speaker

unknown
#68

But in the near term, you don’t believe there are additional candidates that could be marketed?

Werner Baumann

executive
#69

No — near term, the profit contribution is going to come from licensing. And AskBio is already going to give us a positive EBITDA contribution next year. Then, over the medium term, there will also be the other effects from our own pipeline that we'll be able to benefit from. And then, of course, from contract production, as I mentioned earlier.

Operator

operator
#70

Our next question comes in English. <<inaudible>> AFP.

Speaker

unknown
#71

A great deal of media attention has focused on Roundup. I'd like to turn to Essure, which has impacted 40,000 women. Your report states that you're holding resolution talks with counsel representing the remaining plaintiffs. Could you update us on where that stands? What precisely does that entail? And my second question: across this 26-page report — unless my control F search is failing — Brexit never came up. Can you give me a number or figure for the impairment you'd need to record in your annual statement or in next year's earnings in the event of a no-deal cliff-edge Brexit?

Werner Baumann

executive
#72

Thanks for that question. Yes, we made the assured settlement announcement in late August. At that time, we said we'd be paying approximately $1.6 billion in order to resolve about 90% of the 39,000 claims that have been filed and those not filed. Beyond that, the consideration also covers an allowance for cases that haven't been filed as yet. So basically, this represents 100% of the amount for the whole litigation. We're also continuing to move forward on this. We will be making, or already have made, the first payments, and we're in an advanced stage of the resolution process. On your second question, above all, it matters to us that we're able to serve patients in a Brexit scenario as well. This entire situation has been something of a hangover over the past few years. We were well prepared for an uncoordinated Brexit. We remain well prepared for an uncoordinated Brexit. And the key thing here is that our supply chains keep working. That's what we made sure of. Just to give you a sense of how critical that is, the toughest area for us, given your typical customs timelines and so on, is getting our radiopharmaceutical products to patients very quickly, since they are subject to very rapid decay.

Werner Baumann

executive
#73

In addition, we've made available solutions that let us basically deliver on the spot to patients who urgently require these products, since otherwise they're in extremely severe pain. These patients have prostate cancer. Finally, the regulatory framework we should expect following Brexit is going to develop as time goes on, correct? So transitional arrangements will be in place that we understand quite well and that have been examined thoroughly. Therefore we neither expect nor foresee significant adverse effects that would result in, shall we say, asset write-downs. We will observe how the British economy's overall condition develops. Yet that is something that applies in very much the same way to every company conducting business in the U.K., and that's essentially all I can say regarding the Brexit situation.

Operator

operator
#74

And our final question comes once more from the English line, Kevin Roland.

Speaker

unknown
#75

Yes, I had a handful of pharma-related questions. First, has the EMA granted an accelerated assessment for finerenone? Second, you mentioned stringent cost management in Pharma — could you provide some specifics? I mean, clearly with COVID, certain spend or capital spend has disappeared. Can you share more detail? Third, with Europe going back into lockdown, will that slow Eylea's recovery? And how have you been handling competition from Beovu? Finally, could you comment on the Xarelto settlement with Unichem, which I believe was last month? And what is the patent situation for Xarelto in Europe?

Werner Baumann

executive
#76

I apologize for that. Let me begin by addressing where we stand with the pandemic. The lockdown has had a major effect, especially on elective procedures, and Eylea is one of those affected. Eylea took a serious blow during quarter 2. By quarter 3 it had bounced back fully into positive territory, posting growth of plus 2%. Whether the steps governments have put in place — and will keep putting in place — turn out to be harsh is still an open question. Naturally, by this point people have adjusted to living alongside the pandemic. They do a better job of protecting themselves. Even so, I can't offer you any kind of outlook, simply because we don't have the foundation needed to give you a specific one. My hope is that elective treatments will take a smaller hit than they did the first time around, since, to repeat, people have genuinely gotten better at coping with the situation. Turning to the patent picture for Xarelto: the earliest patents will actually lapse in China by the close of this year. Patent protection in China works differently than it does elsewhere. The Chinese market very much still runs along lines like the branded generics segment, which we've benefited from substantially across the past decade plus, and we'll see more debt yields.

Werner Baumann

executive
#77

For most of the other countries, it's largely the 2023–2024 window when we face patent expirations in Europe. The U.S. picture differs somewhat, since we do have a once-daily patent that runs until 2034. We've struck a number of agreements with under filers giving them earlier access, so we expect the exclusivity period — the de facto exclusivity period — may run a bit longer than the patent protection, which, counting the pediatric extension, would otherwise expire in early 2025, yes? So that's about all I can share regarding settlements and the patent situation with Xarelto. On your other question about finerenone, we have communicated and published good clinical data. I can't go further on this call and would ask that — we'll come back to you on that question.

Speaker

unknown
#78

What about the cost basis?

Werner Baumann

executive
#79

Sorry, what was that?

Wolfgang Nickl

executive
#80

Yeah, I can take that one. Sure — what I mean is, we've been tackling expenses across every area. As you'd expect, the pandemic brought substantial savings in travel and event spending automatically. A decent share of that, by the way, is going to stick, since we had invested well in digital interaction with our health care professionals, and that paid off nicely. Clearly, with all flexible spend — consulting, projects that aren't mission-critical — we applied the brakes. And since the business isn't coming in at the growth expectation we initially forecast, we're naturally seeing some savings on the variable incentive programs too. Let me close by noting that we made no cuts to spending on future research and future development. So that point is clear as well.

Werner Baumann

executive
#81

I do have a brief update to share regarding finerenone. So the FIDELIO data will be presented at an upcoming congress — most likely ASN 2020, which is coming up in the near future, still within this year. And we are also in discussions with the relevant health authorities about our data as we prepare to submit our marketing authorization.

Michael Preuss

executive
#82

Good <<interpreted>> Many thanks. Ladies and gentlemen, I truly appreciate your interest, your attention, your questions, and the productive discussion. We hope you have a very good day. And of course, most importantly, stay healthy. Thank you so much.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.